Leucine-rich repeat-containing protein 19 suppresses colorectal cancer by targeting cyclin-dependent kinase 6/E2F1 and remodeling the immune microenvironment

Figure 3 Leucine-rich repeat-containing 19 expression and survival outcomes in colorectal cancer. A: Survival analysis showing no significant differences in disease-free interval (DFI) (P = 0.082) and disease-specific survival (P = 0.092) between high and low leucine-rich repeat-containing 19 (LRRC19) expression groups, but significantly reduced overall survival (OS) (^bP < 0.05) and progression-free interval (^aP < 0.01); B: Differential expression of LRRC19 in normal (n = 41) vs tumor tissues, with significant differences across various comparisons, including sex, pathological type, lymph node status, ethnicity, clinical stage, tumor protein p53 (TP53) mutation status, and body mass index categories (all ^cP < 1 × 10^-12, except Asian ^dP < 1 × 10^-7).